Welcome to our dedicated page for Citius Pharmaceuticals SEC filings (Ticker: CTXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nevada-incorporated biopharmaceutical issuer (Commission File Number 001-38174), Citius Pharmaceuticals reports material events, financing transactions, and other corporate developments through forms such as Form 8-K and registration statements on Form S-3.
In its recent Form 8-K filings, Citius Pharmaceuticals has described securities purchase agreements for registered direct offerings of common stock, pre-funded warrants and common warrants, including details on exercise prices, terms, placement agent arrangements and intended use of proceeds. The company states that net proceeds are expected to support the commercial launch of LYMPHIR, milestone and regulatory payments, development initiatives for its product candidates, and general corporate purposes.
Other 8-K filings referenced by the company include notices of compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement, as well as disclosures about corporate presentations and earnings press releases furnished under Regulation FD and Item 2.02. Together, these filings offer insight into CTXR’s capital strategy, listing status and communication practices with investors.
Through Stock Titan, users can review CTXR’s current and historical SEC documents, including registration statements that underpin shelf offerings and the associated prospectus supplements. The platform pairs these filings with AI-powered summaries designed to clarify key terms, highlight significant financing structures, and explain how reported events relate to the company’s commercialization of LYMPHIR and its late-stage pipeline assets Mino-Lok and CITI-002 (Halo-Lido). This makes it easier to understand complex documents such as 8-Ks, S-3 registration statements, and related exhibits without reading every line of legal text.
Citius Pharmaceuticals, Inc., through its majority-owned subsidiary Citius Oncology, Inc., reports the first international shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe via a regional distribution partner. LYMPHIR will be provided to eligible patients through Named Patient Programs under local regulations, expanding access beyond the United States.
The filing also notes, by reference, a previously closed registered direct offering of common stock and a concurrent private placement of pre-funded, common, and placement agent warrants. LYMPHIR is an FDA-approved targeted immune therapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy and carries a boxed warning for capillary leak syndrome along with detailed safety and use information.
Citius Pharmaceuticals entered into a registered direct offering and concurrent private placement with institutional investors. The company sold 4,730,457 common shares and pre-funded warrants for 345,686 shares at $0.985 and $0.9849, respectively, plus unregistered warrants to purchase up to 5,076,143 shares at $0.86.
Gross proceeds were approximately $5.0 million, with expected net proceeds of about $4.5 million after fees. Citius plans to use the funds to support the commercialization of LYMPHIR™, advance development of its product candidates, and for general corporate purposes.
Citius Pharmaceuticals entered into a registered direct offering and concurrent private placement with institutional investors. The company sold 4,730,457 common shares and pre-funded warrants for 345,686 shares at $0.985 and $0.9849, respectively, plus unregistered warrants to purchase up to 5,076,143 shares at $0.86.
Gross proceeds were approximately $5.0 million, with expected net proceeds of about $4.5 million after fees. Citius plans to use the funds to support the commercialization of LYMPHIR™, advance development of its product candidates, and for general corporate purposes.
Citius Pharmaceuticals is registering 4,730,457 shares of common stock and pre-funded warrants to purchase up to 345,686 shares. The shares are being sold at $0.985 per share and the Pre-funded Warrants at $0.9849 each, with the Pre-funded Warrants exercisable for $0.0001 per share.
The offering includes a concurrent private placement of Common Warrants to purchase up to 5,076,143 shares exercisable at $0.86 (not registered here). Net proceeds to the company are estimated at approximately $4.5 million after placement agent fees. Closing is anticipated on or about April 24, 2026, subject to customary conditions.
Citius Pharmaceuticals is registering 4,730,457 shares of common stock and pre-funded warrants to purchase up to 345,686 shares. The shares are being sold at $0.985 per share and the Pre-funded Warrants at $0.9849 each, with the Pre-funded Warrants exercisable for $0.0001 per share.
The offering includes a concurrent private placement of Common Warrants to purchase up to 5,076,143 shares exercisable at $0.86 (not registered here). Net proceeds to the company are estimated at approximately $4.5 million after placement agent fees. Closing is anticipated on or about April 24, 2026, subject to customary conditions.
Citius Pharmaceuticals, Inc. reported results from its 2026 Annual Meeting of stockholders. Shareholders elected seven directors, including Leonard Mazur and Myron Holubiak, to one-year terms ending at the 2027 annual meeting or until successors are elected and qualified.
Stockholders also ratified Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026, with 8,593,946 shares voting for, 855,866 against and 673,867 abstaining, and no broker non-votes reported on this item.
Citius Pharmaceuticals, through its majority-owned subsidiary Citius Oncology, reported early commercial and clinical progress for LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma. Management estimates the initial LYMPHIR market currently exceeds $400 million and is underserved by existing treatments.
The update highlights growing formulary adoption at leading oncology centers, broadening payer coverage, repeat orders, and adequate commercial supply. Citius Oncology is also expanding clinical development via academic collaborations, including studies in diffuse large B-cell lymphoma and solid tumors in combination with checkpoint inhibitor therapy.
Citius Pharmaceuticals, through its majority-owned subsidiary Citius Oncology, reported positive topline results from an investigator-initiated Phase 1 study of LYMPHIR™ (denileukin diftitox-cxdl) plus pembrolizumab in patients with recurrent or refractory gynecologic cancers.
The study in 25 evaluable patients showed no unexpected safety signals or serious immune-related adverse events at any dose level. Among 21 efficacy-evaluable patients, investigators observed a 24% objective response rate and a 48% clinical benefit rate, defined as complete or partial response or stable disease for at least six months.
The trial aimed to identify a recommended Phase 2 dose, and full safety and efficacy data are planned for presentation at an international cancer conference. LYMPHIR is already FDA‑approved and launched for relapsed or refractory Stage I–III cutaneous T‑cell lymphoma, where management estimates the initial market currently exceeds $400 million.
Citius Pharmaceuticals, through majority-owned subsidiary Citius Oncology, reported positive preliminary Phase 1 data for LYMPHIR when given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. In 14 treated patients, investigators observed an 86% overall response rate, including 57% complete and 29% partial responses, with LYMPHIR described as well tolerated and without dose-limiting toxicities. The study was designed to enhance CAR-T effectiveness by depleting regulatory T-cells, and full results were presented at the 2026 Tandem Meetings. The attached exhibit also reiterates LYMPHIR’s existing FDA approval for cutaneous T-cell lymphoma and includes detailed safety warnings, highlighted by a boxed warning for capillary leak syndrome and other serious risks.
Citius Pharmaceuticals is asking stockholders to vote at its April 6, 2026 annual meeting on electing seven directors for one-year terms and ratifying Wolf & Company, P.C. as auditor for the fiscal year ending September 30, 2026.
Stockholders of record as of February 13, 2026, when 22,376,427 common shares were outstanding, are entitled to one vote per share. A majority of votes represented and entitled to vote is required to elect directors and ratify the auditor. The board reports that five of seven director nominees are independent under Nasdaq rules and highlights its committee structure, executive and director pay practices, and employment and severance arrangements for senior management.
Citius Pharmaceuticals’ major shareholder updates its ownership. CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. report beneficial ownership of 2,394,725 shares of Citius common stock, representing 9.9% of the outstanding shares as of December 31, 2025.
The position includes 799,934 common shares plus additional shares issuable from warrants, which are subject to 4.99% and 9.99% beneficial ownership limits. The reporting parties state the securities are not held for the purpose of changing or influencing control of Citius.